144 institutions hold shares in VYNE Therapeutics Inc. (VYNE), with 1.66M shares held by insiders accounting for 3.23% while institutional investors hold 48.47% of the company’s shares. The shares outstanding are 42.27M, and float is at 41.84M with Short Float at 7.00%. Institutions hold 46.90% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 5.72 million shares valued at $36.14 million. The investor’s holdings represent 11.14% of the VYNE Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 3.0 million shares valued at $18.94 million to account for 5.84% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 1.89 million shares representing 3.67% and valued at over $11.92 million, while Franklin Resources, Inc. holds 3.29% of the shares totaling 1.69 million with a market value of $10.68 million.
VYNE Therapeutics Inc. (NASDAQ: VYNE) is 6.25% higher on its value in year-to-date trading and has touched a low of $4.00 and a high of $13.20 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VYNE stock was last observed hovering at around $6.74 in the last trading session, with the day’s loss setting it -0.02% off its average median price target of $15.00 for the next 12 months. It is also 83.2% off the consensus price target high of $40.00 offered by 7 analysts, but current levels are 32.8% higher than the price target low of $10.00 for the same period.
Currently trading at $6.72, the stock is -4.88% and -19.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.54 million and changing -0.37% at the moment leaves the stock -6.62% off its SMA200. VYNE registered -35.18% loss for a year compared to 6-month gain of 4.27%. The firm has a 50-day simple moving average (SMA 50) of $7.46 and a 200-day simple moving average (SMA200) of $7.44.
The stock witnessed a 0.52% loss in the last 1 month and extending the period to 3 months gives it a 3.63%, and is 4.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.59% over the week and 6.56% over the month.
VYNE Therapeutics Inc. (VYNE) has around 106 employees, a market worth around $340.92M and $21.00M in sales. Distance from 52-week low is 67.88% and -49.13% from its 52-week high. The company has generated returns on investments over the last 12 months (-356.80%).
VYNE Therapeutics Inc. (VYNE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for VYNE Therapeutics Inc. (VYNE) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
VYNE Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.4 with sales reaching $4.68M over the same period.The EPS is expected to grow by 36.30% this year, but quarterly earnings will post 129.30% year-over-year. Quarterly sales are estimated to grow 114.70% in year-over-year returns.
VYNE Therapeutics Inc. (VYNE) Insider Activity
The most recent transaction is an insider purchase by LEPORE PATRICK G, the company’s Director. SEC filings show that LEPORE PATRICK G bought 12,500 shares of the company’s common stock on Mar 15 at a price of $7.41 per share for a total of $92562.0. Following the purchase, the insider now owns 25000.0 shares.
VYNE Therapeutics Inc. disclosed in a document filed with the SEC on Jan 28 that PERCEPTIVE ADVISORS LLC (10% Owner) bought a total of 4,219,409 shares of the company’s common stock. The trade occurred on Jan 28 and was made at $2.37 per share for $10.0 million. Following the transaction, the insider now directly holds 27.1 million shares of the VYNE stock.
Still, SEC filings show that on Dec 03, LEPORE PATRICK G (Director) acquired 50,000 shares at an average price of $1.71 for $85425.0. The insider now directly holds 50,000 shares of VYNE Therapeutics Inc. (VYNE).